Session Information

Free Paper

[FP-FR-20] Late Breaking Abstracts
Go back
print
Day
Apr 04 (Fri)
Time
15:30 - 17:00
Room
Room 9 - Tokyo International Forum 6F G602
Topic
Miscellaneous
Chair/Coordinator
Chair)Peter Wiedemann、Chair)Yuichiro Ogura
Description
Clinical diagnostic and treatment studies are presented which were finished after submission deadline. Topics include diabetes, myopia, vein occlusion, and wet AMD.

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-1 / 

Miscellaneous

Identifying Progression of Retinal Disease in Eyes with Mild NPDR in Diabetes Type 2 Using Non-invasive Procedures

José Cunha-Vaz

Identifying Progression of Retinal Disease in Eyes with Mild NPDR in Diabetes Type 2 Using Non-invasive Procedures

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-2 / 

Miscellaneous

12-Month Results of the Standardized Combination Therapy for Diabetic Macular Edema: Intravitreal Bevacizumab and Navigated Retinal Photocoagulation

Igor Kozak

12-Month Results of the Standardized Combination Therapy for Diabetic Macular Edema: Intravitreal Bevacizumab and Navigated Retinal Photocoagulation

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-3 / 

Miscellaneous

Efficacy and Safety of Intravitreal Aflibercept Injection for Diabetic Macular Edema in Japanese Patients: Analysis of the VIVID-DME, VISTA-DME, and VIVID-Japan Studies

Hiroko Terasaki on Behalf of the VIVID-DME, VISTA-DME and VIVID-Japan Studies

Efficacy and Safety of Intravitreal Aflibercept Injection for Diabetic Macular Edema in Japanese Patients: Analysis of the VIVID-DME, VISTA-DME, and VIVID-Japan Studies

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-4 / 

Miscellaneous

Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema: 3-Year, Randomized, Sham-Controlled Phase III Study

Rubens Belfort Jr.

Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema: 3-Year, Randomized, Sham-Controlled Phase III Study

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-5 / 

Miscellaneous

Ranibizumab Treatment Outcome in Visual Impairment Due to Myopic Choroidal Neovascularization: A Sub Group Analysis of the RADIANCE Study by Baseline Ocular Characteristics

Adnan Tufail

Ranibizumab Treatment Outcome in Visual Impairment Due to Myopic Choroidal Neovascularization: A Sub Group Analysis of the RADIANCE Study by Baseline Ocular Characteristics

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-6 / 

Miscellaneous

Visual Acuity Outcomes and Ranibizumab Treatment Exposure in East-Asian and Caucasian Myopic CNV Patients: A Post Hoc Subgroup Analysis from the RADIANCE Study

Kyoko Ohno-Matsui

Visual Acuity Outcomes and Ranibizumab Treatment Exposure in East-Asian and Caucasian Myopic CNV Patients: A Post Hoc Subgroup Analysis from the RADIANCE Study

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-7 / 

Miscellaneous

BRIGHTER: Ranibizumab with or without Adjunctive Laser vs Laser Alone in Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Ramin Tadayoni

BRIGHTER: Ranibizumab with or without Adjunctive Laser vs Laser Alone in Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-8 / 

Miscellaneous

LUMINOUS: Ranibizumab Treatment in Routine Clinical Practice: One-Year follow-Up Data from the First Cohort of 2000 Patients with Wet Age-Related Macular Degeneration

Paul Mitchell on Behalf of the LUMINOUS study group

LUMINOUS: Ranibizumab Treatment in Routine Clinical Practice: One-Year follow-Up Data from the First Cohort of 2000 Patients with Wet Age-Related Macular Degeneration

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-9 / 

Miscellaneous

Retma: Retinal Expansion Technique for Macular Hole Apposition (A Novel Surgical Technique for Closure of Large Full Thickness Macular Holes)

Roger Wong

Retma: Retinal Expansion Technique for Macular Hole Apposition (A Novel Surgical Technique for Closure of Large Full Thickness Macular Holes)

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-10 / 

Miscellaneous

Vitreous Swept-Source OCT Reveals the Shape and Relationships of the Posterior Precortical Vitreous Pocket, Cloquet's Canal, Prevascular Vitreous Fissures and Perimacular Cisterns

Michael Engelbert

Vitreous Swept-Source OCT Reveals the Shape and Relationships of the Posterior Precortical Vitreous Pocket, Cloquet's Canal, Prevascular Vitreous Fissures and Perimacular Cisterns

Duration 7.5min, Panel Discussion = Last 7.5min

FP-FR-20-11 / 

Miscellaneous

Efficacy and Safety of 0.5 mg Ranibizumab Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Branch Retinal Vein Occlusion Over 6 Months: The COMRADE-B Study

Lars-Olaf Hattenbach

Efficacy and Safety of 0.5 mg Ranibizumab Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Branch Retinal Vein Occlusion Over 6 Months: The COMRADE-B Study

Go back